免疫治疗对比仑伐替尼治疗晚期肝细胞癌的疗效比较:基于目标试验模拟的真实世界分析
该研究利用TriNetX数据库,采用目标试验模拟框架,比较免疫治疗(阿替利珠单抗/贝伐珠单抗或曲美木单抗/度伐利尤单抗)与仑伐替尼一线治疗晚期肝细胞癌的真实世界疗效。倾向性评分匹配后每组纳入1203例,免疫治疗组中位生存545天 vs 仑伐替尼组425天(HR 0.86,95%CI 0.76-0.97)。作者认为免疫治疗与改善总生存相关,支持其作为晚期肝细胞癌一线治疗。
要点
- 倾向性评分匹配后,免疫治疗组中位生存545天 vs 仑伐替尼组425天(HR 0.86,95%CI 0.76-0.97)。
- 阿替利珠单抗联合贝伐珠单抗组对比仑伐替尼组(每组n=1070)HR 0.87,95%CI 0.77-0.99。
- 病毒性肝炎(每组n=510)HR 0.74,95%CI 0.61-0.89;酒精相关肝病(每组n=190)HR 0.65,95%CI 0.49-0.87。
核心结论
- 在晚期肝细胞癌真实世界分析中,免疫治疗相比仑伐替尼与改善总生存相关,且在多数亚组中获益一致。
- 作者认为这些发现支持将免疫治疗作为晚期肝细胞癌的一线治疗。
研究设计与样本
- 利用TriNetX数据库,采用目标试验模拟框架。
- 纳入2018年8月至2023年12月期间接受一线免疫治疗(阿替利珠单抗/贝伐珠单抗或曲美木单抗/度伐利尤单抗)或仑伐替尼的肝细胞癌患者。
- 采用Kaplan-Meier分析和Cox比例风险回归比较总生存,经倾向性评分匹配后每组纳入1203例。
主要发现
- 免疫治疗组中位生存545天 vs 仑伐替尼组425天(HR 0.86,95%CI 0.76-0.97)。
- 阿替利珠单抗联合贝伐珠单抗组对比仑伐替尼组(每组n=1070)HR 0.87,95%CI 0.77-0.99。
- 度伐利尤单抗联合曲美木单抗组对比仑伐替尼组(HR 0.81,95%CI 0.59-1.12)点估计 favor 联合组但未达统计学显著,原文认为可能因样本量小。
- 病毒性肝炎亚组(每组n=510)免疫治疗组对比仑伐替尼组 HR 0.74,95%CI 0.61-0.89。
- 酒精相关肝病亚组(每组n=190)HR 0.65,95%CI 0.49-0.87;代谢功能障碍相关脂肪性肝病亚组(每组n=156)HR 0.96,95%CI 0.70-1.31,未达统计学显著。
临床怎么用
- 作者认为这些发现支持将免疫治疗作为晚期肝细胞癌的一线治疗。
局限性
- 度伐利尤单抗联合曲美木单抗对比仑伐替尼的差异未达统计学显著,原文认为可能因样本量小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Immunotherapy has emerged as an effective treatment for advanced HCC. We aimed to investigate the real-world effectiveness of immunotherapy compared to lenvatinib in HCC. APPROACH AND RESULTS: From the TriNetX database, we used a target trial emulation framework and identified patients with HCC who received first-line treatment with immunotherapy (atezolizumab/bevacizumab or tremelimumab/durvalumab) or lenvatinib between or between August 2018 and December 2023. OS was compared using Kaplan-Meier analysis and Cox proportional hazards regression. After propensity score matching, 1203 patients were included in each group. Immunotherapy was associated with improved OS versus lenvatinib (median survival: 545 vs. 425 d; HR: 0.86, 95% CI: 0.76-0.97). Regarding treatment type, atezolizumab plus bevacizumab showed improved survival compared to lenvatinib (n=1070 in each group; HR: 0.87, 95% CI: 0.77-0.99), while the point estimate favored durvalumab plus tremelimumab versus lenvatinib (HR: 0.81, 95% CI: 0.59-1.12), though this difference was not statistically significant, likely due to small sample size. Regarding etiology, immunotherapy had improved OS compared to lenvatinib in viral hepatitis (n=510 in each group; HR: 0.74, 95% CI: 0.61-0.89) and alcohol-associated liver disease (n=190 in each group; HR: 0.65, 95% CI: 0.49-0.87), but not in metabolic dysfunction-associated steatotic liver diseases (n=156 in each group; HR: 0.96, 95% CI: 0.70-1.31). CONCLUSIONS: In this real-world analysis, immunotherapy was associated with improved OS compared to lenvatinib in advanced HCC, with consistent benefit across most subgroups. These findings support the use of immunotherapy as a first-line treatment for advanced HCC.
引用
- Ahn JC, Ng WH, Yeo YH, et al. Comparative effectiveness of immunotherapy versus lenvatinib in advanced hepatocellular carcinoma: A real-world analysis using target trial emulation. Hepatology. 2025. PMID: 40153442. doi:10.1097/HEP.0000000000001328
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。